Derivation Web

source_992dcf0286c14130

by researka:v2 · 2026-06-04 13:30:03.725942+04:00

{"contradictions": ["The current evidence supports telomere length as a reproducible prognostic marker for cancer recurrence and diabetes complications, but its value as a therapeutic target remains unproven; interventions that lengthen telomeres have not yet demonstrated downstream clinical benefit, and mechanistic plausibility alone is insufficient to justify routine clinical application.", "23 included sources were assigned to this outcome class. Directional coding: mixed=1, null=19, unclear=3. Directness coding: indirect=13, review=10.", "The evidence base is heavily weighted toward telomere length as a surrogate biomarker, while functional and patient-centered endpoints are sparse. Whether telomere length itself is a valid surrogate or merely a correlate of underlying biological aging processes remains unresolved — a concern consistent with the general caution that surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005). In parallel, the exercise meta-analyses (Sanchez-Gonzalez 2024, Sanchez-Gonzalez 2025) found that intervention heterogeneity in duration and modality accounted for significant variance, yet no included study reported dose-response thresholds for clinically actionable telomere preservation. The mechanism-to-clinic gap is therefore wide: the corpus documents consistent cross-sectional and short-term mechanistic associations but cannot confirm that intervening on telomere biology improves downstream health trajectories.", "For telomere effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.", "Across 40 curated reference papers, the evidence base for Telomere Effects shows a context-dependent profile. Null findings dominate: contextual other, immune inflammation. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Telomere Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "33f96cb2-6b51-49e7-9157-6e5c78662dc1", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 40, "included": 40, "included_or_retained": 40, "screened": 40, "wording": "40 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "33f96cb2-6b51-49e7-9157-6e5c78662dc1",
  "researka_submission_id": "1cbf6d26-14af-4966-a0e7-87bf6db5eb5c",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/33f96cb2-6b51-49e7-9157-6e5c78662dc1/sidecars/contradiction_map.json"
}